Products
On the one hand, fibrinogen is commercially available in the form of injection and infusion preparations. On the other hand, products for local treatment are also available, usually containing additional clotting factors (thrombin and possibly factor VIII).
Structure and properties
Fibrinogen is a glycoprotein that circulates in blood plasma. The Pharmacopoeia defines human fibrinogen drug as a sterile, lyophilized preparation of a plasma protein fraction. It contains the soluble component of human plasma, which is converted into fibrin by the addition of thrombin. The substance is obtained from human plasma. The preparation may contain excipients. Fibrinogen is present as a white to pale yellow and hygroscopic powder or friable mass.
Effects
Fibrinogen (ATC B02BB01) replaces missing or insufficient human protein. Fibrinogen plays a central role in the final step of blood clotting. It is converted into a stable and elastic three-dimensional fibrin clot at the end of the clotting cascade. Thrombin and calcium are also required for this process.
Indications
- For prevention and treatment of bleeding in the presence of fibrinogen deficiency.
- Locally to improve hemostasis (hemostasis) and as a tissue adhesive.
Dosage
According to the professional information. The drugs are injected either as an intravenous infusion or as an injection. The route of administration depends on the product. Fibrinogen may also be administered topically.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Adverse effects
Possible adverse effects include when administered parenterally:
- Headache, dizziness
- Fever
- Skin reactions
- Allergic reactions
- Thromboembolic events (isolated cases).
